Virtu Financial LLC Fate Therapeutics Inc Transaction History

Virtu Financial LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 15, 2023	BUY	$9.86 - $23.83 $18,941 - $45,777	1,921 Added 15.16%	14,594 $147,000
Q3 2022 Nov 07, 2022	BUY	$21.04 - $36.06 $266,639 - $456,988	12,673 New	12,673 $284,000
Q2 2021 Sep 17, 2021	SELL	$67.25 - $92.52 $790,792 - $1.09 Million	-11,759 Closed	0 $0
Q1 2021 May 19, 2021	SELL	$72.16 - $117.4 $343,625 - $559,058	-4,762 Reduced 28.82%	11,759 $970,000
Q1 2018 May 14, 2018	SELL	$6.3 - $13.77 $10,899 - $23,822	-1,730 Reduced 9.48%	16,521 $161,000
Q4 2017 Feb 09, 2018	SELL	$3.94 - $6.64 $953 - $1,606	-242 Reduced 1.31%	18,251 $112,000
Q3 2017 Nov 15, 2017	BUY	$2.6 - $4.31 $48,081 - $79,704	18,493	18,493 $0

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.